semaglutide drinking alcohol GLP-1 drugs like Ozempic may curb consumption Alcohol Consumption - what a

DSIP does not appear on the current WADA Prohibited List

What it changes, modestly, is the conversation we have with patients in midlife who are already weighing a GLP-1 decision and have a family history of an obesity-related cancer

About Daiichi Sankyo Group Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose "to contribute to the enrichment of quality of life around the world." In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs

Comparison to Other Senolytic Therapies To contextualise FOXO4-DRI, lets compare it to other senolytic approaches or peptides you may be aware of (helpful given your clinics peptide focus)